Study characterizes cisplatin-induced hearing loss in pediatric cancer patients – News-Medical.Net

Cisplatin is one of the most effective chemotherapy agents, used in just under half of pediatric cancer cases. Permanent hearing loss is a common side effect of this medication, but until now, studies have been too small and too varied to accurately characterize this risk.
Today in The Lancet Child & Adolescent Health, investigators at Children’s Hospital Los Angeles published results of the largest study of cisplatin-induced hearing loss to date. The study establishes the first benchmarks for the…

Click here to view the original article.